Array BioPharma Inc.’s $150 Million At-The-Market Equity Program


Simpson Thacher represented Jefferies LLC in an SEC-registered at-the-market equity program pursuant to which shares of Array BioPharma Inc.’s (“Array”) (NYSE: ARRY) common stock, having an aggregate sales price of up to $150 million, may be sold from time to time by Jefferies LLC, as sales agent.

Array is a fully integrated, biopharmaceutical company focused on the discovery, development and commercialization of target small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

The Simpson Thacher team included John C. Ericson (Picture), Ashley Yoon and Arielle Trapp (Capital Markets); Vanessa Burrows (Healthcare); Jonathan Cantor and Abigail Hopper (Tax); Elizabeth Gladstone (Intellectual Property); and Nathan Utterback (Executive Compensation and Employee Benefits).

Involved fees earner: Vanessa Burrows – Simpson Thacher & Bartlett; Jonathan Cantor – Simpson Thacher & Bartlett; John Ericson – Simpson Thacher & Bartlett; Elizabeth Gladstone – Simpson Thacher & Bartlett; Abigail Hopper – Simpson Thacher & Bartlett; Arielle Trapp – Simpson Thacher & Bartlett; Nathan Utterback – Simpson Thacher & Bartlett; Ashley Sunha Yoon – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: Jefferies;

Avatar

Author: Ambrogio Visconti